KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $677000.0.

  • Esperion Therapeutics' Non Operating Income fell 5726.01% to $677000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 5412.29%. This contributed to the annual value of $8.0 million for FY2024, which is 5161.6% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Non Operating Income of $677000.0 as of Q3 2025, which was down 5726.01% from $666000.0 recorded in Q2 2025.
  • Esperion Therapeutics' Non Operating Income's 5-year high stood at $3.9 million during Q4 2021, with a 5-year trough of $9000.0 in Q2 2021.
  • Moreover, its 5-year median value for Non Operating Income was $1.1 million (2023), whereas its average is $1.2 million.
  • Over the last 5 years, Esperion Therapeutics' Non Operating Income had its largest YoY gain of 1631250.0% in 2021, and its largest YoY loss of 9619.57% in 2021.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Non Operating Income stood at $3.9 million in 2021, then plummeted by 65.6% to $1.4 million in 2022, then dropped by 20.3% to $1.1 million in 2023, then rose by 11.76% to $1.2 million in 2024, then plummeted by 43.91% to $677000.0 in 2025.
  • Its Non Operating Income stands at $677000.0 for Q3 2025, versus $666000.0 for Q2 2025 and $1.1 million for Q1 2025.